Cancer Immunotherapy News and Research

RSS

Researchers suggest new approach to slow cancer growth using tumor-derived dendritic cells

In the human body, so-called dendritic cells are responsible for activating our immune system. While researchers previously believed that tumors could repress these dendritic cells - blocking an adequate natural cancer defense mechanism - a new study has painted a more positive picture.

25 Jan 2017

Research offers new clues to prolong lifespan of the body's disease-fighting NK cells

A team of researchers from Australia and France have uncovered new insights into how to prolong the lifespan of the body's disease-fighting natural killer (NK) cells.

17 Jan 2017

Cancers acquire resistance to immunotherapy by eliminating tumor-specific genetic mutations

Results of an initial study of tumors from patients with lung cancer or head and neck cancer suggest that the widespread acquired resistance to immunotherapy drugs known as checkpoint inhibitors may be due to the elimination of certain genetic mutations needed to enable the immune system to recognize and attack malignant cells.

6 Jan 2017

New research suggests novel combination approach to fight against gliomas

"Devastating" and "dismal." That's how leading researchers describe the present outlook for malignant brain tumors. The median survival rate for patients with glioblastoma multiforme, or GBM, is a mere 14.2 months.

4 Jan 2017

Study suggests new options for improving cancer immunotherapy

One of the main reasons cancer remains difficult to treat is that cancer cells have developed a multitude of mechanisms that allow them to evade destruction by the immune system.

30 Dec 2016

Nanodiscs deliver customized therapeutic vaccine for treatment of colon, melanoma cancers

Researchers at the University of Michigan have had initial success in mice using nanodiscs to deliver a customized therapeutic vaccine for the treatment of colon and melanoma cancer tumors.

27 Dec 2016

Experimental T-cell therapy shows promise in preventing AML relapse

Fred Hutchinson Cancer Research Center announced promising results from an early trial in which patients with high-risk acute myeloid leukemia received genetically engineered immune cells.

6 Dec 2016

Compugen program shows potential for development of new immunotherapy treatments for solid tumors

Compugen Ltd., a leading predictive drug discovery company, today presented new data for its preclinical CGEN-15029 program demonstrating the potential for the development of new cancer immunotherapy treatments for solid tumors, including the potential for drug combination with current immune checkpoint blockers.

11 Nov 2016

Weight loss condition provides clues to why cancer immunotherapy may fail in many patients

A weight loss condition that affects patients with cancer has provided clues as to why cancer immunotherapy - a new approach to treating cancer by boosting a patient's immune system -- may fail in a substantial number of patients.

8 Nov 2016

Fred Hutchinson opens first-of-its-kind clinic to provide new immunotherapies for cancer patients

Fred Hutchinson Cancer Research Center today announced the official opening of a first-of-its-kind clinic dedicated to providing innovative immunotherapies for cancer patients in clinical trials.

2 Nov 2016

New approach could overcome large immunosuppressive tumors

Harnessing the body's own immune system to destroy tumors is a tantalizing prospect that has yet to realize its full potential. However, a new advance from MIT may bring this strategy, known as cancer immunotherapy, closer to becoming reality.

24 Oct 2016

Scientists modify structure of cancer drug to enhance ability to pass through blood-brain barrier

In efforts to develop new treatments for brain cancer, scientists from Johns Hopkins Drug Discovery and the Kimmel Cancer Center's Bloomberg~Kimmel Institute for Cancer Immunotherapy report they have altered the structure of an experimental drug that seems to enhance its ability to slip through the mostly impermeable blood-brain barrier.

20 Oct 2016

Mount Sinai awarded $10 million grant to explore cellular, molecular mechanisms of GVHD

Researchers from the Icahn School of Medicine at Mount Sinai have been awarded a $10 million from the National Cancer Institute to explore the cellular and molecular mechanisms of acute graft-versus-host disease (GVHD), a common side effect that occurs after allogeneic bone marrow transplantation (BMT), and to develop novel therapeutic strategies for BMT patients with cancer that begin in the cells of blood-forming tissue or hematologic malignancies.

13 Oct 2016

Houston Methodist researcher receives $4 million to create triple negative breast cancer immunotherapy

Scientists at Houston Methodist received support from the U.S. Department of Defense to reprogram cancer patients' immune cells to attack triple negative breast cancer, the most lethal form of breast cancer.

13 Oct 2016

Ludwig researchers shed more light on key requirement for function of regulatory T cells

A Ludwig Cancer Research study published online September 5th in Nature Immunology illuminates a key requirement for the function of regulatory T cells—immune cells that play a critical role in many biological processes, from suppressing inflammation and deadly autoimmunity to helping tumors evade immune attack.

23 Sep 2016

Researchers discover new strategy to boost effectiveness of anti-cancer immune therapy

Researchers at University of California San Diego School of Medicine and Moores Cancer Center have identified a strategy to maximize the effectiveness of anti-cancer immune therapy.

19 Sep 2016

Pathologists to collaborate on promise, challenges of immunotherapy at CAP16

At the College of American Pathologists annual meeting this month, more than 1,300 pathologists will collaborate on the promise, challenges, and questions surrounding immunotherapy—the subject of the opening Scientific Plenary at CAP16 - The Pathologists' Meeting in Las Vegas on Sept. 25.

14 Sep 2016

NIBIB researchers develop nanovaccine to enhance cancer immunotherapy

NIBIB researchers have created a nanovaccine that could make a current approach to cancer immunotherapy more effective while also reducing side effects.

25 Aug 2016

Immunotherapy innovations in oncology: an interview with Robert LaCaze

The body’s immune system is an excellent weapon against many diseases. For more than 100 years, immunology and immunotherapy have played an ever-increasing role in the understanding and treatment of cancer.

8 Aug 2016

Experimental immunotherapeutic strategy may pave way for new treatments against lymphoma

Lymphoma is a cancer that affects lymphocytes, a type of white blood cell. The disease originates in a lymphoid organ (lymph node, spleen, or bone marrow) before spreading through the blood to infiltrate not only other lymphoid organs but also other tissues.

4 Aug 2016